Chronic HBV Infection in Pregnant Women Taking TAF to Prevent Vertical Transmission

UnknownOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

April 9, 2019

Primary Completion Date

September 30, 2020

Study Completion Date

September 30, 2020

Conditions
Hepatitis B, ChronicPregnancy Related
Interventions
DRUG

Tenofovir Alafenamide 25 MG

Tenofovir Alafenamide 25 mg, per oral daily was taken by CHB pregnant mothers with viral load ≥ 2 × 10\^6 IU / mL from gestational week 28 to delivery of infant to prevent MTCT.

DRUG

Tenofovir Disoproxil Fumarate 300 MG Oral Tablet

Tenofovir Disoproxil Fumarate 300 mg, per oral daily was taken by CHB pregnant mothers with viral load ≥ 2 × 10\^6 IU / mL from gestational week 28 to delivery of infant to prevent MTCT.

Trial Locations (4)

100069

RECRUITING

Beijing You'an Hospital, Capital Medical University, Beijing

150001

RECRUITING

Department of Infectious Disease,The Fourth Affiliated Hospital of Harbin Medical University, Harbin

066000

RECRUITING

The Third Hospital of Qinhuangdao City, Qinhuangdao

028000

RECRUITING

Tongliao Infectious Disease Hospital, Tongliao

Sponsors

Lead Sponsor

All Listed Sponsors
lead

New Discovery LLC

INDUSTRY

NCT04237376 - Chronic HBV Infection in Pregnant Women Taking TAF to Prevent Vertical Transmission | Biotech Hunter | Biotech Hunter